Marc Bailie, DVM, PhD
Prior to his role as the Director of the In Vivo Pharmacology Center, Dr. Bailie spent eleven years at Parke-Davis/Pfizer, developing and directing the Safety Pharmacology Group within Drug Safety Research and Development. He has extensive experience in a broad array of models for the evaluation of
pharmacologic and toxicologic activity of compounds. During his tenure in the pharmaceutical development arena he served on numerous Discovery and Development project teams, provided scientific direction for safety pharmacology both locally and on a global basis, and
served as expert council for cardiovascular and general safety pharmacology, both within and outside of Pfizer.
While at Pfizer, Dr. Bailie contributed significantly to the co-development and characterization of novel animal models to assess the impact of pharmaceutical agents on parameters of cardiac conduction and function.
Teresa Krieger-Burke, DVM, PhD
Dr. Krieger-Burke is the Associate Director of the Center. She has extensive drug development experience, having worked in Drug Safety at Parke-Davis/Pfizer for over six years. Her areas of expertise include general toxicology, reproductive toxicology, and safety pharmacology. She has extensive experience serving as a study director and subject matter expert across the pharmaceutical development process.
During her tenure at Pfizer, she contributed significantly to development and implementation of the scientific and regulatory strategy within Global Safety Pharmacology. Dr. Krieger-Burke has served on various Discovery and Development project teams and has interacted with the FDA as part of these efforts. Dr. Krieger-Burke is a graduate of Michigan State University and of the University of Michigan. She has published in textbooks and peer-reviewed journals in areas of reproductive toxicology and oxidative stress, and currently serves on the Nominating Committee of the Safety Pharmacology Society.
Bari Olivier, DVM, PhD, Dipl. ACVIM
Dr. Olivier is an Associate Professor of Veterinary Cardiology (board certified). He has over 25 years of experience as a clinical cardiologist and over 20 years experience as a scientific investigator. He is an expert in advanced cardiac diagnostics, including electrocardiography, echocardiography, cardiac and coronary catheterizations. Dr. Olivier heads one of the few clinical and experimental electrophysiology (EP) animal labs in the country. He has over 10 years of experience in clinical and experimental cardiac electrophysiology. He has developed new animal models for testing cardiac safety of drugs and has conducted numerous related tests of compounds under contract arrangements with pharmaceutical companies.
J. Justin McCormick, PhD
Dr. McCormick’s major research interests and experience include cellular and molecular mechanisms of carcinogenesis, chemical and radiation carcinogenesis, mutagenesis and malignant transformation of human cells, anti-cancer effects of chemical agents, environmental toxicology, and DNA repair. In 1992 he was named a University Distinguished Professor at Michigan State University, and he has been a faculty member of the Department of Microbiology and Molecular Genetics at Michigan State University for more than 25 years.
Gregory Fink, PhD
Dr. Fink is an expert in experimental design and statistical analysis of research data. He has nearly 35 years of research experience in the fields of cardiovascular physiology, pharmacology, and disease. Dr. Fink’s principal experimental approach is to perform studies on intact, conscious animals with chronically implanted measurement devices. Dr. Fink’s laboratory has conducted numerous efficacy and safety tests on drugs under contract arrangements with a variety of pharmaceutical and biotechnology companies.
Stephanie Watts, PhD
Dr. Watts is dedicated to understanding the mechanisms by which arteries and veins contribute to hypertension in the hopes of developing novel treatments. Her lab has a history of investigating ‘non-classical’ pathways or signal transduction mechanisms for smooth muscle contraction. Dr. Watts has also conducted evaluations of compounds under contract with several pharmaceutical companies. She has served as an Associate Editor for the Journal of Pharmacology and Experimental Therapeutics since 2005. Most recently she was named Chair of Vascular Keystone Symposium on Vascular Smooth Muscle for 2009 to be held in Vancouver, British Columbia.
James Galligan, PhD
Dr. Galligan’s research interests focus primarily on neural control of gastrointestinal (GI) motility and blood flow. Dr. Galligan has consulted for a number of pharmaceutical companies with interests in gastrointestinal drugs, including Novartis, TAP Pharmaceuticals, Roche Pharmaceuticals, Procter and Gamble, MGI Pharmaceuticals, and Takeda
Pharmaceuticals.In 2004, he received the Janssen Award for Basic Science Research in Gastrointestinal Motility and in 2005 he was invited to present the Jim Long Memorial Lecture at the annual meeting of the American Motility Society.
Anne Dorrance, PhD
Dr. Dorrance’s research interests focus primarily on hypertension and stroke. A Professor of Pharmacology and Toxicology at Michigan State University, she is studying how hypertension affects the structure and function of the cerebral blood vessels. Dr. Dorrance’s lab uses a wide variety of in vivo and in vitro techniques in an effort to correlate the damage caused by an ischemic stroke with the structure of the cerebral vessels.
Joseph R. Haywood, PhD
Dr. Haywood has worked in the area of mechanisms of hypertension for over 30 years. This focus has been on the impact of humoral factors on the central nervous system. His interests have included the physiology and pharmacology of the renin-angiotensin system and sympathetic nervous system in sodium dependent and obesity dependent hypertension in conscious samples. In 2002, he became Professor and Chair of the Department of Pharmacology & Toxicology at Michigan State University after many years at the University of Texas Health Science Center in San Antonio. He has served on numerous editorial boards and national committees. He has been an advocate for the humane use of animals in research and teaching and served nine years on AAALAC Council on Accreditation.
Sarah Marsh, BS, LVT
Sarah Marsh brings over eight years of combined client-owned and research animal experience. A graduate of Michigan State University with a Bachelor of Science in Veterinary Technology, she worked at the Michigan State University teaching hospital in the Intensive Care Unit, Anesthesia, and Orthopedics departments. While working with leading specalists
in these areas, she developed the right set of skills to effectively transition to research. In 2004 she joined Drug Safety department at Pfizer. While at Pfizer, she developed her technical expertise and study directing capabilities within a GLP environment. She has contributed extensively to the conduct and reporting of both General Toxicology and Safety Pharmacology studies.